SGX301 treatment response continues to demonstrate highly statistically significant improvement after 12 weeks of therapy Response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold Reinforces positive SGX301 primary endpoint treatment response demonstrating statistical significance after 6 weeks of therapy Princeton, NJ – April 30, 2020… Read More..
NEW YORK, April 28, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has released its annual letter to shareholders. In… Read More..
Kuuhubb’s flagship game Recolor sees its Android Monthly Active Users (MAU) grow by 214%, resulting in over 30% growth of Recolor Android revenue for the month of March 2020 TORONTO, April 22, 2020 (GLOBE NEWSWIRE) -- Kuuhubb Inc. (“Kuuhubb” or the “Company”) (TSXV: KUU), a publicly listed mobile game development… Read More..